Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Inflammatory Bowel Diseases

Free Subscription 21.05.2018 6 Dig Dis Sci 2 Eur J Gastroenterol Hepatol 1 Gastroenterol Hepatol 1 Gastroenterology 2 Inflamm Bowel Dis 1 J Clin Gastroenterol 5 J Crohns Colitis 1 Scand J Gastroenterol

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Dig Dis Sci

1. COHEN-MEKELBURG S, Tafesh Z, Coburn E, Weg R, et al
   Testing and Treating Small Intestinal Bacterial Overgrowth Reduces Symptoms in Patients with Inflammatory Bowel Disease.
   Dig Dis Sci. 2018 May 14. pii: 10.1007/s10620-018-5109.
   PubMed     Text format     Abstract available
   
   
2. CHETCUTI ZAMMIT S, McAlindon ME, Hale MF, Sidhu R, et al
   Isolated Terminal Ileitis: When Is It Not Crohn's Disease?
   Dig Dis Sci. 2018;63:1367.
   PubMed     Text format    
   
   
3. MOGILEVSKI T, Sparrow MP
   Infliximab Versus Adalimumab in Patients with Biologic-Naive Crohn's Disease: Is the Difference Real?
   Dig Dis Sci. 2018;63:1094-1096.
   PubMed     Text format    
   
   
4. CAVOUNIDIS A, Uhlig HH
   Crohn's Disease in Niemann-Pick Disease Type C1: Caught in the Cross-Fire of Host-Microbial Interactions.
   Dig Dis Sci. 2018;63:811-813.
   PubMed     Text format    
   
   
5. KUSAKA J, Shiga H, Kuroha M, Kimura T, et al
   Residual Lesions on Capsule Endoscopy Is Associated with Postoperative Clinical Recurrence in Patients with Crohn's Disease.
   Dig Dis Sci. 2018;63:768-774.
   PubMed     Text format     Abstract available
   
   
6. LUTHER J, Gala M, Patel SJ, Dave M, et al
   Loss of Response to Anti-Tumor Necrosis Factor Alpha Therapy in Crohn's Disease Is Not Associated with Emergence of Novel Inflammatory Pathways.
   Dig Dis Sci. 2018;63:738-745.
   PubMed     Text format     Abstract available
   
   

   
   Eur J Gastroenterol Hepatol

7. SCHOEPFER A, Vavricka SR, Brungger B, Reich O, et al
   Systematic analysis of annual health resource utilization and costs in hospitalized patients with inflammatory bowel disease in Switzerland.
   Eur J Gastroenterol Hepatol. 2018 May 11. doi: 10.1097/MEG.0000000000001160.
   PubMed     Text format     Abstract available
   
   
8. CARDILE S, Candusso M, Papadatou B, Bracci F, et al
   Lack of efficacy of infliximab in the treatment of primary sclerosing cholangitis in inflammatory bowel diseases in childhood.
   Eur J Gastroenterol Hepatol. 2017;29:736.
   PubMed     Text format    
   
   

   
   Gastroenterol Hepatol

9. GISBERT JP, Chaparro M
   Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review.
   Gastroenterol Hepatol. 2018 May 9. pii: S0210-5705(18)30108.
   PubMed     Text format     Abstract available
   
   

   
   Gastroenterology

10. PARISINOS CA, Serghiou S, Katsoulis M, George MJ, et al
    Variation in Interleukin 6 Receptor Gene Associates with Risk of Crohn's Disease and Ulcerative Colitis.
    Gastroenterology. 2018 May 15. pii: S0016-5085(18)34542.
    PubMed     Text format     Abstract available
    
    

    
    Inflamm Bowel Dis

11. BEGGS AD, James J, Caldwell G, Prout T, et al
    Discovery and Validation of Methylation Biomarkers for Ulcerative Colitis Associated Neoplasia.
    Inflamm Bowel Dis. 2018 May 14. pii: 4995684. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
12. BIANCARDI AL, Zaltman C, Troncoso LL, Luiz RR, et al
    The Role of Clinical-Demographic Characteristics in Ophthalmic Manifestations of Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2018 May 11. pii: 4995039. doi: 10.1093.
    PubMed     Text format    
    
    

    
    J Clin Gastroenterol

13. SHAH A, Walker M, Burger D, Martin N, et al
    Link Between Celiac Disease and Inflammatory Bowel Disease.
    J Clin Gastroenterol. 2018 May 14. doi: 10.1097/MCG.0000000000001033.
    PubMed     Text format     Abstract available
    
    

    
    J Crohns Colitis

14. SANDBORN WJ, Bhandari BR, Randall C, Younes ZH, et al
    Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease.
    J Crohns Colitis. 2018 May 14. pii: 4996034. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
15. LAMB CA, O'Byrne S, Keir ME, Butcher EC, et al
    Gut-selective integrin-targeted therapies for inflammatory bowel disease.
    J Crohns Colitis. 2018 May 15. pii: 4996111. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
16. CUSHING KC, Kordbacheh H, Gee MS, Kambadakone A, et al
    Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients.
    J Crohns Colitis. 2018 May 12. pii: 4995527. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
17. YANG C, Huang J, Huang X, Huang S, et al
    Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Alpha Agents: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2018 May 12. pii: 4995526. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
18. LEE CK, Wong SH, Lui G, Tang W, et al
    A prospective study to monitor for tuberculosis during anti-tumour necrosis factor therapy in patients with inflammatory bowel disease and immune mediated inflammatory diseases.
    J Crohns Colitis. 2018 May 11. pii: 4994967. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    Scand J Gastroenterol

19. WALDUM HL, Bjornsson ES, Brenna E
    Chronic cholestatic liver diseases.
    Scand J Gastroenterol. 2017 Feb 28:1. doi: 10.1080/00365521.2017.1296276.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: